Acquisition of Praha Vaccines a.s. (Tables)

6 Months Ended

Jun. 30, 2020

Acquisition of Praha Vaccines a.s.

Summary of preliminary allocation of the Purchase Price based upon the fair values of assets acquired and liabilities assumed at the Acquisition Date

The table below summarizes the preliminary allocation of the Purchase Price based upon the fair values of assets acquired and liabilities assumed at the Acquisition Date. The preliminary allocation is based upon information that was available to management at the time the consolidated financial statements were prepared and is subject to change prior to completion of the measurement period (in thousands):

Prepaid expense and other current assets	$	326
Property and equipment		96,739
Goodwill		70,468
Accounts payable		(1,193)
Accrued expenses		(205)
Other non-current liabilities		(813)
Purchase Price, net of cash acquired	$	165,322

Summary of unaudited pro forma financial information

The unaudited pro forma financial information for the periods set forth below gives effect to the Acquisition as if it had occurred as of January 1, 2019.  The pro forma financial information is presented for informational purposes only and is not necessarily indicative of the results of operations that would have been achieved had the Acquisition been consummated as of that time. The unaudited pro forma financial information combines the historical results of operations of the Company and Praha Vaccines for the periods presented below and reflects the application of certain pro forma adjustments (in thousands, except per share amounts):

	Three Months Ended				Six Months Ended
	June 30,				June 30,
	2020		2019		2020		2019
Revenue	$	35,538	$	3,357	$	38,915	$	7,339
Net loss		(18,196)		(42,119)		(45,821)		(87,367)
Basic and diluted net loss per share		(0.31)		(0.97)		(0.83)		(2.08)